Figure 6. DiFiD inhibits SCC growth in vivo.
(A) DiFiD treatment protocol for xenograft studies. HN5/FaDu (1 x 106) cells were inoculated subcutaneously into the right flank of athymic Foxn1nu/nu mice. DiFiD (2 mg/kg) or vehicle control (DMSO) was administered by intraperitoneal injection once daily for 15 days. (B) HN5 tumor volumes (n=7 mice/group) are depicted. (C) HN5 xenograft tumors were subjected to biomarker analyses. Representative immunoblots from a small cohort of HN5 xenograft tumors were probed for Bax, cyclin D1 and DCLK1. (D) FaDu tumor volumes (n=10 mice/group) are depicted. (E) Representative immunoblots from a small cohort of FaDu xenograft tumors were probed as in (C). ASCC PDX was transplanted into the flanks of NSG mice. DiFiD (2 mg/kg) or vehicle control (DMSO) was administered by intraperitoneal injection once daily for 15 days. (F) Fractional tumor volume and weight (G) are depicted (n=10 mice/group for control and n=14 mice/group for DiFiD treatment). Error bars represent ± SEM. *p<0.05, ***p<0.001.